AU2019315444B2 - Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers - Google Patents

Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers Download PDF

Info

Publication number
AU2019315444B2
AU2019315444B2 AU2019315444A AU2019315444A AU2019315444B2 AU 2019315444 B2 AU2019315444 B2 AU 2019315444B2 AU 2019315444 A AU2019315444 A AU 2019315444A AU 2019315444 A AU2019315444 A AU 2019315444A AU 2019315444 B2 AU2019315444 B2 AU 2019315444B2
Authority
AU
Australia
Prior art keywords
cancer
halo
alkyl
alkoxy
metastatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019315444A
Other languages
English (en)
Other versions
AU2019315444A1 (en
Inventor
Mark Esposito
Yibin Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of AU2019315444A1 publication Critical patent/AU2019315444A1/en
Application granted granted Critical
Publication of AU2019315444B2 publication Critical patent/AU2019315444B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019315444A 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers Active AU2019315444B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712434P 2018-07-31 2018-07-31
US62/712,434 2018-07-31
PCT/US2019/044278 WO2020028461A1 (en) 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Publications (2)

Publication Number Publication Date
AU2019315444A1 AU2019315444A1 (en) 2021-02-11
AU2019315444B2 true AU2019315444B2 (en) 2024-10-31

Family

ID=67734803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019315444A Active AU2019315444B2 (en) 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Country Status (8)

Country Link
US (2) US12162855B2 (https=)
EP (1) EP3830079A1 (https=)
JP (1) JP7613743B2 (https=)
CN (1) CN112638881B (https=)
AU (1) AU2019315444B2 (https=)
CA (1) CA3107120A1 (https=)
IL (1) IL280395B2 (https=)
WO (1) WO2020028461A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016316A1 (en) * 2014-08-01 2016-02-04 Nuevolution A/S Compounds active towards bromodomains

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126270A (ja) * 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS61145162A (ja) * 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3701277A1 (de) 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPH01319453A (ja) * 1988-06-22 1989-12-25 Wakamoto Pharmaceut Co Ltd 新規ベンゾキノン誘導体
MXPA05012086A (es) 2003-05-12 2006-02-22 Pfizer Prod Inc Inhibidores de benzamida del receptor p2x7.
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
JP2006349902A (ja) * 2005-06-15 2006-12-28 Fujifilm Holdings Corp 黒白熱現像感光材料
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
KR102319882B1 (ko) * 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
WO2015173169A1 (en) 2014-05-12 2015-11-19 Fondazione Istituto Italiano Di Tecnologia Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016316A1 (en) * 2014-08-01 2016-02-04 Nuevolution A/S Compounds active towards bromodomains

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1153285-30-3; STN Entry Date 7 June 2009 *
CAS Registry Number 1154533-72-8; STN Entry Date 9 June 2009 *
CAS Registry Number 1292643-91-4; STN Entry Date 10 May 2011 *
CAS Registry Number 1303823-01-91; STN Entry Date June 2011 *
CAS Registry Number 1304933-67-2; STN Entry Date 3 June 2011 *
CAS Registry Number 1306404-60-3; STN Entry Date 6 June 2011 *
CAS Registry Number 1308446-19-6; STN Entry Date 10 June 2011 *
CAS Registry Number 1468571-74-5; STN Entry Date 3 November 2013 *
CAS Registry Number 1798740-10-9; STN Entry Date 10 July 2015 *
CAS Registry Number 1875411-98-5; STN Entry Date 28 February 2016 *
CAS Registry Number 2094666-41-6; STN Entry Date 2 May 2017 *
CAS Registry Number 2195663-27-3; STN Entry Date 21 March 2018 *
CAS Registry Number 874534-18-5; STN Entry Date 26 February 2016 *
Journal of Chemical Information and Modeling, 2017, vol. 57, no. 6, pages 1309-1320. *
Journal of Medicinal Chemistry, 2011, vol. 54, no. 24, pages 8563-8573. *

Also Published As

Publication number Publication date
IL280395B2 (en) 2025-04-01
WO2020028461A1 (en) 2020-02-06
JP7613743B2 (ja) 2025-01-15
CN112638881B (zh) 2025-01-07
CA3107120A1 (en) 2020-02-06
US20210155602A1 (en) 2021-05-27
EP3830079A1 (en) 2021-06-09
US12162855B2 (en) 2024-12-10
CN112638881A (zh) 2021-04-09
JP2021532158A (ja) 2021-11-25
AU2019315444A1 (en) 2021-02-11
IL280395A (en) 2021-03-01
US20250129046A1 (en) 2025-04-24
IL280395B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US20250129046A1 (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
US9221764B2 (en) Inhibitors of inv(16) leukemia
JP6126233B2 (ja) 新たなキノリン類の化合物及びその使用
US20130116277A1 (en) Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
KR20160003196A (ko) ＂니코틴아미드 포스포리보실트랜스퍼라제의 억제제, 조성물, 제품 및 그의 용도＂
Wei et al. Discovery of SILA-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations
WO2014039820A1 (en) Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
JP2025518287A (ja) リン化合物とそれの使用
KR20110002872A (ko) 안드로겐 수용체의 소분자 억제제
Mohammed et al. Synthesis and biological evaluation of 4H-benzo [e][1, 3] oxazin-4-ones analogues of TGX-221 as inhibitors of PI3Kβ
CN107141287B (zh) 2-亚胺-5-酮基-2,5-二氢-1-h-二吡啶并嘧啶类化合物
JP7445609B2 (ja) Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途
HK40049062A (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
HK40049062B (zh) 用於治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
US12570661B2 (en) Isoform-specific aldehyde dehydrogenase inhibitors
Zhang et al. Zhijian Li2, 4, Huiran Qiu1, 4, Wenxia Lu1, 4, Namin Duan2, 4, Shule Fan1, Rui Zhou2, Xiangzhi Li1
Han et al. Discovery of the thieno [2, 3-b][1, 4] thiazin-2 (3H)-one STING inhibitors
Shao et al. Novel Indoline Derivatives as Ferroptosis Inhibitors: Synthesis, Biological Evaluation, and Mechanistic Investigation
JP2025521593A (ja) ３βＨＳＤ１阻害剤及び組成物ならびにそれらの使用
TW202521112A (zh) 新穎化合物、及用於預防或治療癌症或腫瘤之包含該化合物的醫藥組成物
TWI635080B (zh) 具抗雄激素性質新雜芳醯胺衍生物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)